CMV Detection Using Conserved UL34 and UL80.5 Primer Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cytomegalovirus (CMV) in biological samples, such as plasma and whole blood, face challenges in sensitivity, specificity, and reproducibility due to sequence variation among CMV strains, leading to inadequate detection of active infections and potential false negatives or false positives.
Innovation Solution
The use of specific oligonucleotide primers and probes targeting the UL34 and UL80.5 regions of the CMV genome, which are highly conserved across strains, for nucleic acid amplification and detection in real-time PCR assays, ensuring robust, sensitive, and reproducible results.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional PCR methods are used for CMV detection, then the detection process is simple, but the sensitivity and specificity are insufficient due to sequence variation among CMV strains
Solution Approach 1:
The patent changes the target parameter from generic CMV DNA to specific conserved regions (UL34 and UL80.5) of the CMV genome. By selecting primer and probe binding sites within highly conserved regions that show minimal sequence variation across different CMV strains, the assay achieves superior sensitivity and specificity while maintaining operational simplicity
Solution Approach 2:
The patent uses real-time PCR with fluorescent probes to detect and quantify CMV DNA. The fluorescent probes (such as TaqMan probes) serve as molecular copies that specifically bind to the conserved UL34 and UL80.5 regions, allowing for precise measurement of viral load through fluorescence signal intensity that correlates with the amount of target DNA
2Reliability
If viral culture methods are used for CMV detection, then direct diagnostic information is obtained, but the method is technically difficult and does not enable rapid diagnosis
Solution Approach 1:
The patent replaces the mechanical and time-consuming viral culture process with a nucleic acid-based amplification system. Real-time PCR directly amplifies and detects CMV DNA from clinical samples without requiring virus cultivation, reducing diagnostic time from days to hours while maintaining or improving diagnostic accuracy through specific detection of viral genomic sequences
Solution Approach 2:
The patent performs preliminary amplification of the target DNA sequences before detection. By using PCR to amplify the conserved UL34 and UL80.5 regions prior to probe-based detection, the method ensures sufficient target material is available for reliable detection, enabling rapid and accurate diagnosis without the time required for viral culture
3Productivity
If PCR with conventional primers is used, then amplification occurs, but false positives and false negatives occur due to sequence variation among CMV strains
Solution Approach 1:
The patent applies local quality by selecting specific regions (UL34 and UL80.5) within the CMV genome that possess unique properties - high conservation across strains. The primers and probes are designed to bind specifically to these locally conserved regions, ensuring that the amplification and detection processes are both efficient and accurate across diverse CMV strains without cross-reactivity or failure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables reliable detection of CMV in various biological samples, improving the sensitivity and specificity of CMV detection, allowing for early diagnosis and monitoring of active infections, and predicting the response to antiviral therapy.
Implementation Method 1
One of the pair of primers for amplification of a UL34 nucleic acid sequence can specifically hybridize to the UL34 CDS in the region from about nucleotide 2 to about nucleotide 29, and the other of the pair of primers for amplification of a UL34 nucleic acid sequence can specifically hybridize to the UL34 CDS in the region from about nucleotide 78 to about nucleotide 106
Implementation Method 2
subjecting the mixture to conditions that promote amplification of the UL34 nucleic acid sequence and the UL80.5 nucleic acid sequence
Implementation Method 3
The probe for detection of amplification of a UL34 nucleic acid sequence can specifically hybridize to the UL34 CDS in the region from about nucleotide 29 to about nucleotide 79
Data Source
AI summary
A method of amplifying cytomegalovirus (CMV) nucleic acid sequences in a sample comprising (a) forming a mixture comprising the sample, amplification reagents, and pairs of primers for amplification of UL34 and UL80.5 nucleic acid sequences, and (b) subjecting the mixture to conditions that promote amplification, wherein the method can further comprise (c) detecting the presence, amount or concentration of CMV in the sample, in which case the mixture in (a) can further comprise probes for detection of amplification of UL34 and UL80.5 nucleic acid sequences; a set of primers comprising pairs of forward and reverse primers for amplification of UL34 and UL80.5 nucleic acid sequences; a set of probes comprising probes for detection of amplification of UL34 and UL80.5 nucleic acid sequences; and a kit comprising (i) sets of primers for amplification of UL34 and UL80.5 nucleic acid sequences and (ii) instructions for using the sets of primers and/or one or more reagents for using the sets of primers, wherein the kit can further comprise (i) probes for detection of amplification of UL34 and UL80.5 nucleic acid sequences and (ii) instructions for using the probes and/or one or more reagents for using the probes.